Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to -$65.1 million.

  • Praxis Precision Medicines' Cash from Operations fell 13657.09% to -$65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$228.9 million, marking a year-over-year decrease of 13002.43%. This contributed to the annual value of -$131.8 million for FY2024, which is 1855.47% down from last year.
  • Praxis Precision Medicines' Cash from Operations amounted to -$65.1 million in Q3 2025, which was down 13657.09% from -$54.7 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year Cash from Operations high stood at -$20.9 million for Q1 2024, and its period low was -$65.1 million during Q3 2025.
  • Moreover, its 4-year median value for Cash from Operations was -$32.8 million (2023), whereas its average is -$40.0 million.
  • In the last 5 years, Praxis Precision Medicines' Cash from Operations soared by 4831.81% in 2023 and then plummeted by 15415.93% in 2025.
  • Quarter analysis of 4 years shows Praxis Precision Medicines' Cash from Operations stood at -$28.8 million in 2022, then rose by 17.17% to -$23.9 million in 2023, then crashed by 135.2% to -$56.1 million in 2024, then decreased by 15.92% to -$65.1 million in 2025.
  • Its last three reported values are -$65.1 million in Q3 2025, -$54.7 million for Q2 2025, and -$53.0 million during Q1 2025.